Scholarlink

Introduction <p>Anticancer drugs are administered near the maximum tolerated dose, and their therapeutic range is significantly narrower compared to conventional drugs. Even for expensive anticancer drugs, some of the drug in the vial is used, whereas the remainder is discarded.</p> Objective <p>Because body size impacts dosage and varies significantly among racial groups, in this study, we aimed to assess the impact of dose adjustment on healthcare expenses and bevacizumab dose fluctuations in Japan.</p> Methods <p>We investigated the effects of bevacizumab dosage variation and the degree of dose adjustment on medical costs based on annual bevacizumab use data from the National Database of Health (NDB) Open Data. Additionally, a multicentre, retrospective study was conducted at four national university hospitals to record bevacizumab consumption. We analysed the impact of dose adjustments in the ranges of 10%, 5%, and 2% on drug costs.</p> Results <p>Simulations based on this data estimated potential cost savings. The use of bevacizumab has been steadily increasing: 1.59 million vials were used in Japan in 2021, costing JPY 101.6 billion. Dose adjustments of 10%, 5%, and 2% could reduce costs by approximately JPY 4,619,699,806, 1,777,439,323, and 420,016,889 per year, respectively. Dose adjustments for bevacizumab could significantly reduce healthcare costs in Japan.</p> Conclusion <p>Numerous anticancer drugs exist beyond bevacizumab, and similar cost-reduction measures applied to these drugs could lead to further savings. Although prospective clinical trials are needed to assess the impact of dose adjustments on treatment effectiveness, significant healthcare cost reductions are anticipated if this approach proves effective.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effective drug dosage rounding reduces healthcare expenses in the Japanese healthcare system

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月24日

查看全文
  • Kenta Yagi,
  • Makoto Kajizono,
  • Akinori Maruo,
  • Wataru Shinmura,
  • Yuuki Nitta,
  • Toshihiko Yoshioka,
  • Masayuki Chuma,
  • Shunsuke Ishida,
  • Tsukasa Higashionna,
  • Hiroaki Tanaka,
  • Fuka Aizawa,
  • Takahiro Niimura,
  • Mitsuhiro Goda,
  • Kei Kawada,
  • Yuki Izawa-Ishizawa,
  • Yoshito Zamami,
  • Shinji Kosaka,
  • Yoshikazu Tasaki,
  • Keisuke Ishizawa

摘要

Introduction

Anticancer drugs are administered near the maximum tolerated dose, and their therapeutic range is significantly narrower compared to conventional drugs. Even for expensive anticancer drugs, some of the drug in the vial is used, whereas the remainder is discarded.

Objective

Because body size impacts dosage and varies significantly among racial groups, in this study, we aimed to assess the impact of dose adjustment on healthcare expenses and bevacizumab dose fluctuations in Japan.

Methods

We investigated the effects of bevacizumab dosage variation and the degree of dose adjustment on medical costs based on annual bevacizumab use data from the National Database of Health (NDB) Open Data. Additionally, a multicentre, retrospective study was conducted at four national university hospitals to record bevacizumab consumption. We analysed the impact of dose adjustments in the ranges of 10%, 5%, and 2% on drug costs.

Results

Simulations based on this data estimated potential cost savings. The use of bevacizumab has been steadily increasing: 1.59 million vials were used in Japan in 2021, costing JPY 101.6 billion. Dose adjustments of 10%, 5%, and 2% could reduce costs by approximately JPY 4,619,699,806, 1,777,439,323, and 420,016,889 per year, respectively. Dose adjustments for bevacizumab could significantly reduce healthcare costs in Japan.

Conclusion

Numerous anticancer drugs exist beyond bevacizumab, and similar cost-reduction measures applied to these drugs could lead to further savings. Although prospective clinical trials are needed to assess the impact of dose adjustments on treatment effectiveness, significant healthcare cost reductions are anticipated if this approach proves effective.